Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our unique technology to address current and emerging threats.

Novavax continually conducts clinical trials and investigations and gathers real-world evidence to develop vaccines aimed at addressing public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of patients who take part in our trials.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Vaccines in Novavax Pipeline and Status
Therapeutic area
Candidate
Adjuvant Technology
Phase of trial
Authorized use
   
Preclinical
Phase 1
Phase 2
Phase 3
 
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine1
Matrix-M™ adjuvant
    
 
Authorized
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
Matrix-M™ adjuvant
  
 
Phase 2
 
Sponsored by the University of Oxford
Parasitic diseases
Malaria
R21
Matrix-M™ adjuvant
    
 
Authorized
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine1
 
Authorized
Matrix-M™ adjuvant
Respiratory diseases
COVID-19 + seasonal influenza
COVID-influenza combination (CIC) vaccine
 
Phase 2
Matrix-M™ adjuvant
Parasitic diseases
Malaria
R21
 
Authorized
Matrix-M™ adjuvant
Sponsored by the University of Oxford

Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™, and authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula); Ongoing post-authorization Phase 3 strain change trial. For the full list of countries where we are authorized, please visit https://novavaxcovidvaccine.com.


‡ Authorized in Ghana, Nigeria, and Burkina Faso; Commercialized by Serum Institute of India and granted prequalification by the WHO. Vaccine and trial sponsored by University of Oxford in collaboration with Serum Institute of India with Matrix-M adjuvant.

Science & Technology

From the diseases that we're focused on to the details of our scientific approach

Science & Technology

Source in-depth information, including select clinical trial protocols

Who we are

Novavax is powered by global collaborations